Wednesday, July 22, 2015
Eolas Therapeutics, a therapeutic development company based in Carlsbad, Calif., has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics (BPN) grant from the NIH for the development of the program from the preclinical stage through phase I clinical trials.
The ALS Association, Harvard Stem Cell Institute and Massachusetts General Hospital Neurological Clinical Research Institute are collaborating with GlaxoSmithKline on a clinical trial to evaluate the potential of an anti-epileptic drug in ALS patients. In parallel testing, brain cells will be made from each patient’s stem cells to see if they can predict which patients might respond to the medicine.
A NIH-led public-private partnership to transform and accelerate drug development has launched a new Alzheimer’s Big Data portal—including delivery of the first wave of data—for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, FDA, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies.
MRIGlobal, an independent, nonprofit CRO based in Kansas City, Mo., has been awarded a $54 million, 10-year program from the National Institute of Neurological Disorders and Stroke to provide support for the development and manufacturing of drug candidates for ultimate use in human clinical trials.
Nine groups of scientists will receive funding totaling $5.9 million in 2014 to work together on increasing the understanding of sudden unexpected death in epilepsy (SUDEP), the leading cause of death from epilepsy. The consortium becomes the second Center Without Walls, an initiative to speed the pace of research on difficult problems in epilepsy by promoting collaborative research. The U.S. National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, funds this initiative.
The NIH, as part of a research partnership with the Patient-Centered Outcomes Research Institute (PCORI), has issued a request for applications (RFA) to study how to improve blood pressure control among populations at highest risk for suffering hypertension-related strokes, heart attacks and other cardiovascular events. PCORI is a Wash. D.C.-based independent nonprofit organization authorized by Congress.
The NIH will award three large, five-year projects on a specific form of dementia, known as frontotemporal because of the areas of the brain that are affected. The projects, funded by the NIH’s National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Aging (NIA) and the National Center for Advancing Translational Sciences (NCATS), will receive more than $5.9 million for 2014.
Aethlon Medical and its New Jersey-based diagnostic subsidiary Exosome Sciences (ESI) have established a clinical collaboration with the Boston University (BU) CTE Center to advance a blood-based diagnostic candidate that could identify Chronic Traumatic Encephalopathy (CTE) in living individuals.